- Home
- SPRY vs IRON Comparison
SPRY vs IRON Comparison
Compare SPRY & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- IRON
- Stock Information
- Founded
- SPRY 2015
- IRON 2017
- Country
- SPRY United States
- IRON United States
- Employees
- SPRY 160
- IRON N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- SPRY Health Care
- IRON Health Care
- Exchange
- SPRY Nasdaq
- IRON Nasdaq
- Market Cap
- SPRY 1.4B
- IRON 1.4B
- IPO Year
- SPRY N/A
- IRON N/A
- Fundamental
- Price
- SPRY $13.44
- IRON $44.24
- Analyst Decision
- SPRY Strong Buy
- IRON Strong Buy
- Analyst Count
- SPRY 4
- IRON 10
- Target Price
- SPRY $28.75
- IRON $83.80
- AVG Volume (30 Days)
- SPRY 1.2M
- IRON 403.4K
- Earning Date
- SPRY 05-14-2025
- IRON 05-07-2025
- Dividend Yield
- SPRY N/A
- IRON N/A
- EPS Growth
- SPRY N/A
- IRON N/A
- EPS
- SPRY 0.08
- IRON N/A
- Revenue
- SPRY $89,149,000.00
- IRON N/A
- Revenue This Year
- SPRY $1.49
- IRON N/A
- Revenue Next Year
- SPRY $141.68
- IRON N/A
- P/E Ratio
- SPRY $168.00
- IRON N/A
- Revenue Growth
- SPRY 297063.34
- IRON N/A
- 52 Week Low
- SPRY $7.55
- IRON $28.25
- 52 Week High
- SPRY $18.51
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- SPRY 46.69
- IRON 45.99
- Support Level
- SPRY $13.06
- IRON $40.36
- Resistance Level
- SPRY $15.06
- IRON $47.21
- Average True Range (ATR)
- SPRY 0.67
- IRON 2.87
- MACD
- SPRY -0.18
- IRON 0.10
- Stochastic Oscillator
- SPRY 15.97
- IRON 37.67
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.